Study Eligibility Criteria
| Component | Description |
|---|---|
| FDA = Food and Drug Administration; HbA1c=glycated hemoglobin. | |
| Population | Adults and children with type 1 or type 2 diabetes |
| Intervention | Pramlintide for FDA- and non-FDA-approved indications |
| Compared agent | Other hypoglycemic agent or placebo |
| Long-term health outcomes | All-cause mortality, micro- or macrovascular disease, quality of life, complications related to diabetes |
| Intermediate outcomes | Glycemic control: HbA1c, fasting plasma glucose, postprandial glucose; change in weight; time to treatment failure |
| Harms-related outcomes | Withdrawals due to all causes, withdrawals due to adverse events, overall adverse events, major adverse events |
| Study design | For efficacy/effectiveness: randomized controlled clinical trials, good-quality systematic reviews
 For harms and subgroups: randomized controlled clinical trials, good-quality systematic reviews, population-based comparative cohort or case-control studies |
| Excluded | Trials <12 weeks’ duration; abstracts, posters, and conference proceedings with limited information for quality assessment |